Hazim El-Haddad, MD
Interventional Cardiology · Falls Church, VANPI 1033439443
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Medtronic at 56.4% of the total.
Across 258 payments — averaging $152.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$22K
- Abbott$9K
- Edwards Lifesciences$5K
- W. L. Gore & Associates, Inc.$855
- Philips North America LLC$822
- E.r. Squibb & Sons, L.L.C.$141
- plus $1K from 22 others
What the payments were for
- Consulting fees$6,05615%
- Travel & lodging$23,10259%
- Food & beverage$10,16126%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 65 | $22,176 |
| Abbott | 82 | $9,448 |
| Edwards Lifesciences | 32 | $4,724 |
| W. L. Gore & Associates, Inc. | 18 | $855 |
| Philips North America LLC | 5 | $822 |
| E.r. Squibb & Sons, L.L.C. | 9 | $141 |
| Sanofi-aventis U.S. LLC | 2 | $138 |
| Boston Scientific | 2 | $132 |
| Chiesi USA, Inc. | 2 | $115 |
| Johnson & Johnson | 7 | $110 |
| Novartis | 5 | $106 |
| Abiomed | 4 | $92 |
| Amgen | 4 | $76 |
| Kestra Medical Technology Services, Inc. | 2 | $58 |
| Bridgebio Pharma, Inc. | 2 | $46 |
| Boehringer Ingelheim | 2 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| Cleerly, Inc. | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Heartflow, Inc. | 1 | $21 |
| Pfizer | 1 | $18 |
| Merit Medical Systems Inc | 3 | $18 |
| Cvrx, Inc. | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$19,619
- MitraClip$3,030
- TRICLIP$1,726
- EVOQUE$1,579
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,285
- Mitra Clip system$1,165
- CoreValve Evolut$908
- IGT Devices Und$600
- CARDIOFORM Septal Occluder$457
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$274
- AMPLATZER TALISMAN$176
- VIABAHN Endoprosthesis$173
- AMPLATZER PICCOLO$168
- (9148) ICE 3D$124
- PRALUENT$120
- GENERAL - STENTS$119
- KENGREAL$105
- 3F$105
How this compares
$39,329 in reported general payments places this provider in the 85th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $37,629 |
| Rosuvastatin Calcium | 12 | $401 |
| ClopidogrelClopidogrel Bisulfate | 17 | $367 |
| Atorvastatin Calcium | 24 | $170 |
| Furosemide | 19 | $134 |
| Metoprolol Succinate | 13 | $102 |
| Losartan Potassium | 12 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $18 | $37,62922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Falls Church
- Noah JonesFalls Church$238K
- Wayne BatchelorFalls Church$196K
- Matthew SherwoodFalls Church$193K
- Lindsey CiliaFalls Church$50K
- Nadim GelooFalls Church$41K
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Michael GenVirginia Beach$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.